PharmaKinetics Laboratories Inc., the troubled Baltimore pharmaceutical services company, announced yesterday that Max L. Mendelsohn has been named vice president for business development and client services.
Mr. Mendelsohn, who joined PharmaKinetics in January, was president of Barre-National Inc., a subsidiary of A. L. Laboratories Inc. of Fort Lee, N.J. He is taking over for Cindy Schurick, who is taking a part-time position "for personal reasons," PharmaKinetics said.
The company also announced that Ruth Randolph-Boulter, an account manager, has been promoted to director of sales.
The personnel changes come after a tumultuous year for PharmaKinetics, which tests pharmaceutical drugs for other companies before they are made available for widespread distribution.
Last year the company filed for Chapter 11 bankruptcy protection after it ended a contract with Bolar Pharmaceuticals, which accounted for about 45 percent of the Baltimore company's revenue. Bolar ultimately pleaded guilty to criminal charges of selling adulterated and mislabeled generic drugs and paid a $10 million fine.
In June PharmaKinetics pleaded guilty to obstructing a federal investigation and was fined $200,000.
The company's current president and chief executive officer, V. Brewster Jones, took over a year ago after the resignation of then-CEO Steven A. Woodman, whose father founded the company.
Mr. Mendelsohn's former company, Barre-National, manufactures liquid drugs such as cough syrups and ointments. It was founded by Mr. Mendelsohn's father as the Barre Drug Co. and was acquired in 1969 by R. S. Revco Inc.
A. L. Laboratories bought the Revco subsidiary in 1987 for $95 million, and Mr. Mendelsohn and his two brothers left the firm three years later.